Pfizer, Athersys are in a licensing deal for stem cell therapy

12/21/2009 | NYTimes.com

Pfizer agreed to pay biotech firm Athersys as much as $111 million to gain rights to MultiStem, a stem cell therapy being developed to treat heart attack and cancer patients undergoing a bone marrow transplant. The companies hope the cells will produce proteins that will help heal or prevent damage in existing tissue.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID